GO:0061757 leukocyte adhesion to arterial endothelial cell: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061757 describes the attachment of a leukocyte to an arterial endothelial cell via adhesion molecules, a discrete step in the inflammatory recruitment cascade.
• This process is initiated by endothelial activation, in which cytokines and oxidized lipids induce adhesion molecules such as VCAM-1, ICAM-1, and selectins on arterial endothelium.
• Signaling through p38 MAPK alpha and NF-kappaB is a central regulatory axis for endothelial adhesion molecule expression and subsequent leukocyte attachment.
• Mitochondrial fission and endothelial CD40L have been identified as additional modulators of endothelial inflammation and leukocyte adhesion.
• Leukocyte adhesion to arterial endothelium is a critical early event in atherosclerosis and has been implicated in thoracic aortic aneurysm formation in Marfan disease.
• Experimental models including knockout, point-mutation, knock-in, and overexpression cell lines enable causal interrogation of genes controlling this process.
Description
Leukocyte adhesion to arterial endothelial cell (GO:0061757) is a biological process defined as the attachment of a leukocyte to an arterial endothelial cell via adhesion molecules. This term captures a specific cellular interaction that occurs when circulating leukocytes engage adhesion receptors presented on the surface of arterial endothelial cells. The process is a discrete, experimentally observable step within the broader leukocyte recruitment cascade and is distinguished from rolling, firm arrest on other vessel types, and transendothelial migration. Because arterial endothelial cells exhibit distinct phenotypic and hemodynamic properties compared with venous or capillary endothelium, the molecular players and regulatory logic of leukocyte adhesion in arteries have been studied as a distinct problem in vascular biology. The importance of GO:0061757 for researchers lies in its causal proximity to inflammatory vascular disease. Atherosclerosis is now widely understood as an inflammatory process in which leukocyte recruitment to the arterial wall is an initiating and sustaining event. Endothelial activation, driven by cytokines and oxidized lipids, induces adhesion molecules that mediate leukocyte attachment, and interventions that suppress this step reduce vascular inflammation in experimental systems. The term therefore serves as a functional annotation node that links gene products to a measurable cellular phenotype with direct relevance to cardiovascular pathology. From a methods perspective, GO:0061757 is assayable using static and flow-based adhesion assays, endothelial activation models, and genetic perturbation of candidate genes. Recent studies have used endothelial cell activation with cytokines followed by leukocyte attachment readouts to test the role of p38 MAPK alpha and NF-kappaB signaling, mitochondrial dynamics, and endothelial CD40L. These approaches make the term tractable for CRISPR-based functional genomics and for mechanistic studies of arterial inflammation.
leukocyte adhesion to arterial endothelial cell At A Glance
| GO ID | GO:0061757 |
|---|---|
| GO term | leukocyte adhesion to arterial endothelial cell |
| Ontology | biological_process |
| Synonym | none |
| Definition | The attachment of a leukocyte to an arterial endothelial cell via adhesion molecules. |
| Major function | Mediates the initial attachment of leukocytes to activated arterial endothelium during inflammation. |
| Cellular context | Arterial endothelial cell surface and leukocyte plasma membrane. |
| Key molecular players | Adhesion molecules including selectins, integrins, VCAM-1, and ICAM-1. |
| Disease relevance | Atherosclerosis, vascular inflammation, and thoracic aortic aneurysm in Marfan disease. |
What Is GO:0061757?
In plain terms, GO:0061757 describes the moment a white blood cell sticks to the inner lining of an artery. More formally, it is the biological process in which a leukocyte attaches to an arterial endothelial cell through adhesion molecules. The definition emphasizes three elements: the leukocyte as the attaching cell, the arterial endothelial cell as the substrate, and adhesion molecules as the molecular mediators. It does not by itself specify rolling, firm arrest, or transmigration, although these related events often precede or follow attachment in vivo.
Why Is leukocyte adhesion to arterial endothelial cell Important in Cell Biology?
GO:0061757 is important because leukocyte adhesion to arterial endothelium is a proximal, measurable event in inflammatory vascular disease. Atherosclerosis is recognized as an inflammatory disorder in which leukocyte recruitment to the arterial wall contributes to lesion initiation and progression. Experimental suppression of endothelial activation and adhesion molecule expression reduces leukocyte attachment and vascular inflammation, indicating that this step is causally relevant and potentially modifiable. The term also provides a structured annotation target for interpreting gene function in cardiovascular research, allowing investigators to connect specific genes to a defined cellular phenotype.
• Defines a discrete, assayable step in the leukocyte recruitment cascade specific to arterial endothelium.
• Links endothelial activation signals such as p38 MAPK alpha and NF-kappaB to a functional adhesion phenotype.
• Provides a mechanistic entry point for studying atherosclerosis as an inflammatory disease.
• Implicates mitochondrial dynamics in endothelial inflammation and leukocyte attachment.
• Highlights endothelial CD40L as a pro-atherogenic adhesion receptor in inflamed vasculature.
• Connects arterial leukocyte adhesion to thoracic aortic aneurysm formation in Marfan disease.
• Supports drug discovery efforts targeting endothelial activation and adhesion molecule expression.
• Enables CRISPR-based causal testing of candidate genes in endothelial-leukocyte interaction models.
What Happens During leukocyte adhesion to arterial endothelial cell?
Endothelial activation and adhesion molecule induction
In simple terms: The artery lining becomes sticky because inflammatory signals turn on sticky proteins on its surface.
The process begins when arterial endothelial cells are activated by inflammatory mediators such as cytokines and oxidized lipids. This activation induces the expression of adhesion molecules on the endothelial surface, including VCAM-1 and ICAM-1, which are required for leukocyte attachment. Signaling through p38 MAPK alpha and NF-kappaB has been shown to drive endothelial cell activation and adhesion molecule expression, and inhibition of these pathways reduces leukocyte attachment. Endothelial CD40L has also been identified as a pro-atherogenic adhesion receptor that contributes to leukocyte engagement in the inflamed vasculature.
Leukocyte capture and attachment
In simple terms: White blood cells grab onto the sticky artery lining and stick in place.
Once adhesion molecules are expressed, circulating leukocytes attach to the arterial endothelial surface via adhesion molecule interactions. This attachment step is the defining event of GO:0061757. Experimental studies have measured leukocyte attachment to activated endothelial cells as a readout of this process, and interventions that reduce adhesion molecule expression correspondingly reduce leukocyte attachment. The attachment is mediated by adhesion molecules on both the leukocyte and endothelial cell surfaces, consistent with the GO definition.
Mitochondrial dynamics as a modulator of endothelial inflammation
In simple terms: The energy-producing parts of the cell can change shape to influence how inflamed the artery lining becomes.
Mitochondrial fission has been identified as a mediator of endothelial inflammation. Experimental work shows that mitochondrial fission contributes to endothelial inflammatory responses that support leukocyte adhesion. This finding expands the mechanistic scope of GO:0061757 beyond classical adhesion molecule transcription, indicating that organelle dynamics can modulate the arterial endothelial phenotype relevant to leukocyte attachment.
Annexin A8 and atherosclerosis progression
In simple terms: A protein called Annexin A8 affects how quickly artery plaques develop.
Annexin A8 deficiency has been reported to delay atherosclerosis progression, linking a specific gene product to the broader disease process in which leukocyte adhesion to arterial endothelium participates. While the precise molecular connection between Annexin A8 and the adhesion step requires further study, this finding illustrates how genes can be evaluated for their contribution to arterial inflammatory biology relevant to GO:0061757.
Myeloperoxidase and arterial wall pathology
In simple terms: An enzyme from immune cells can worsen artery wall damage in a genetic connective tissue disease.
Myeloperoxidase has been shown to aggravate thoracic aortic aneurysm formation in Marfan disease, indicating that leukocyte-derived enzymes contribute to arterial wall pathology in which leukocyte-endothelial interactions are relevant. This observation connects the cellular process described by GO:0061757 to a specific genetic vascular disease context and supports further investigation of adhesion-dependent mechanisms in aneurysm formation.
Key Genes Involved in GO:0061757 leukocyte adhesion to arterial endothelial cell
The following genes and proteins have been experimentally implicated in endothelial activation, adhesion molecule expression, or leukocyte attachment relevant to GO:0061757.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VCAM-1 | Endothelial adhesion molecule that binds leukocyte integrins | Marker of endothelial activation and mediator of leukocyte attachment |
| ICAM-1 | Endothelial adhesion molecule that supports leukocyte firm adhesion | Target for assessing endothelial activation and leukocyte attachment |
| CD40L | Endothelial adhesion receptor in inflamed vasculature | Pro-atherogenic adhesion receptor implicated in leukocyte engagement |
| p38 MAPK alpha | Kinase driving endothelial activation and adhesion molecule expression | Inhibition reduces leukocyte attachment and vascular inflammation |
| NF-kappaB | Transcription factor inducing adhesion molecule expression | Central regulator of endothelial activation |
| Annexin A8 | Protein whose deficiency delays atherosclerosis progression | Candidate gene for arterial inflammatory biology |
| Myeloperoxidase | Leukocyte-derived enzyme that aggravates arterial wall pathology | Implicated in thoracic aortic aneurysm in Marfan disease |
| Selectins | Adhesion molecules mediating initial leukocyte capture | Classical mediators of leukocyte-endothelial interactions |
| Integrins | Leukocyte adhesion receptors binding endothelial ligands | Required for leukocyte attachment to endothelium |
| Mitochondrial fission machinery | Organelle dynamics modulating endothelial inflammation | Modulates endothelial inflammatory phenotype |
| Crizanlizumab target (P-selectin) | Adhesion molecule targeted in sickle cell disease | Illustrates therapeutic targeting of adhesion in vascular disease |
| Oxidized LDL | Inflammatory lipid inducing endothelial activation | Drives adhesion molecule expression in atherogenesis |
| Cytokines (e.g., TNF, IL-1) | Inflammatory mediators activating endothelium | Used experimentally to induce adhesion molecule expression |
| Chemokines | Recruit leukocytes to activated endothelium | Support leukocyte recruitment to arterial wall |
| Nitric oxide synthase | Endothelial enzyme modulating vascular inflammation | Relevant to endothelial activation state |
| Prostaglandin pathway enzymes | Modulate vascular inflammation | Contribute to inflammatory milieu of arterial wall |
| Matrix metalloproteinases | Remodel arterial wall during inflammation | Linked to aneurysm and plaque progression |
How Is leukocyte adhesion to arterial endothelial cell Regulated?
The process of leukocyte adhesion to arterial endothelial cell is regulated primarily at the level of endothelial activation. Inflammatory cytokines and oxidized lipids induce signaling through p38 MAPK alpha and NF-kappaB, which drives adhesion molecule expression and subsequent leukocyte attachment; pharmacological inhibition of these pathways reduces leukocyte attachment and vascular inflammation. Mitochondrial fission has been identified as an additional regulatory input that modulates endothelial inflammation. Endothelial CD40L functions as a pro-atherogenic adhesion receptor in the inflamed vasculature, providing another layer of regulation. Together, these findings indicate that GO:0061757 is controlled by convergent inflammatory signaling and organelle dynamics rather than by a single linear pathway.
leukocyte adhesion to arterial endothelial cell and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VCAM-1 | Atherosclerosis and endothelial activation | Endothelial knockout or overexpression cell lines with leukocyte adhesion assay |
| CD40L | Pro-atherogenic vascular inflammation | Endothelial CD40L knockout and knock-in cell models |
| Annexin A8 | Atherosclerosis progression | Annexin A8 knockout endothelial cells and atherosclerosis models |
| Myeloperoxidase | Thoracic aortic aneurysm in Marfan disease | Myeloperoxidase knockout or overexpression models in arterial cells |
| p38 MAPK alpha | Endothelial activation and vascular inflammation | Point-mutation and knockout endothelial cells with adhesion assays |
Atherosclerosis
Atherosclerosis is an inflammatory disease of arteries in which leukocyte recruitment to the arterial wall is a central pathogenic event. Leukocyte adhesion to arterial endothelial cells, the process described by GO:0061757, represents an early and mechanistically tractable step in this cascade. Endothelial activation and adhesion molecule expression are required for leukocyte attachment, and interventions that suppress these events reduce vascular inflammation in experimental models. Annexin A8 deficiency has been reported to delay atherosclerosis progression, further linking specific gene products to arterial inflammatory biology.
Thoracic aortic aneurysm in Marfan disease
Myeloperoxidase has been shown to aggravate thoracic aortic aneurysm formation in Marfan disease, indicating that leukocyte-derived inflammatory mediators contribute to arterial wall pathology. Because leukocyte adhesion to arterial endothelium is a prerequisite for leukocyte accumulation in the vessel wall, this disease context provides a rationale for investigating GO:0061757-related mechanisms in aneurysm formation.
Sickle cell disease and adhesion-targeted therapy
Crizanlizumab, a therapeutic agent used in sickle cell disease, targets an adhesion molecule, illustrating that adhesion biology is clinically actionable in vascular disease. While the specific adhesion events in sickle cell disease differ from arterial leukocyte adhesion as defined by GO:0061757, this example demonstrates the broader principle that adhesion molecule blockade can modify vascular pathology.
From leukocyte adhesion to arterial endothelial cell-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for leukocyte adhesion to arterial endothelium? | Knockout endothelial cell line with leukocyte attachment assay |
| Does a specific kinase activity mediate adhesion molecule induction? | Point-mutation knock-in of kinase-dead or constitutively active allele |
| Does a risk variant alter adhesion molecule expression? | Knock-in of the variant allele in endothelial cells |
| Where does a candidate protein localize during leukocyte attachment? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of an adhesion molecule increase leukocyte attachment? | Overexpression endothelial cell line with adhesion assay |
| Which genes modulate endothelial activation in a genome-wide manner? | CRISPR library screening in endothelial cells with adhesion readout |
How to Study the leukocyte adhesion to arterial endothelial cell Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Static leukocyte adhesion assay | Number of leukocytes attached to endothelial monolayer | Testing gene requirement for attachment |
| Flow-based adhesion assay | Leukocyte attachment under shear stress | Modeling arterial hemodynamics |
| RNA-seq | Transcript levels of adhesion molecules and inflammatory genes | Assessing endothelial activation |
| Flow cytometry | Surface protein expression of VCAM-1, ICAM-1, selectins | Quantifying adhesion molecule induction |
| CRISPR knockout | Loss-of-function effect on leukocyte attachment | Causal gene testing |
| CRISPR point mutation | Effect of specific amino acid change on function | Dissecting signaling domains |
| Tagged knock-in | Protein localization and interaction | Imaging adhesion machinery |
| Overexpression | Gain-of-function effect on adhesion | Testing sufficiency of a candidate gene |
Static and flow-based leukocyte adhesion assays
Leukocyte adhesion to arterial endothelial cells can be measured using static or flow-based adhesion assays in which labeled leukocytes are incubated with activated endothelial monolayers and attached cells are quantified. These assays have been used to demonstrate that inhibition of p38 MAPK alpha and NF-kappaB reduces leukocyte attachment. The readout directly corresponds to the attachment event defined by GO:0061757.
Endothelial activation and adhesion molecule expression profiling
Endothelial cells can be activated with cytokines or oxidized lipids, followed by measurement of adhesion molecule expression using RNA-seq, qPCR, or flow cytometry. This approach links upstream signaling to the adhesion molecule induction step required for leukocyte attachment. Expression profiling of VCAM-1 and ICAM-1 is commonly used as a surrogate for endothelial activation status.
Genetic perturbation with CRISPR
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in endothelial cells. For example, perturbation of signaling genes can be combined with leukocyte adhesion assays to determine whether a gene is required for attachment. This strategy is applicable to genes such as CD40L, Annexin A8, and mitochondrial fission regulators.
In vivo arterial inflammation models
Animal models of atherosclerosis and aortic aneurysm provide a physiological context for studying leukocyte adhesion to arterial endothelium. Myeloperoxidase has been studied in Marfan disease-associated thoracic aortic aneurysm, and Annexin A8 deficiency has been evaluated in atherosclerosis progression. These models complement cell-based adhesion assays by linking the cellular process to disease outcomes.
How CRISPR Can Be Used to Study GO:0061757 leukocyte adhesion to arterial endothelial cell
Knockout
CRISPR knockout of candidate genes in arterial endothelial cells enables loss-of-function testing of whether a gene is required for leukocyte adhesion. For example, knockout of signaling components in the p38 MAPK alpha and NF-kappaB pathway would be expected to reduce adhesion molecule expression and leukocyte attachment. Knockout models are also suitable for testing genes such as CD40L and Annexin A8 in adhesion assays.
Point Mutation
CRISPR point mutation allows precise modification of specific residues to test their role in endothelial activation and leukocyte attachment. This approach is useful for dissecting kinase catalytic activity, phosphorylation sites, or receptor binding interfaces relevant to adhesion molecule function. Point-mutation models provide mechanistic resolution beyond simple knockout.
Knock-in
CRISPR knock-in can be used to introduce disease-associated variants, reporter tags, or epitope tags into endogenous loci. Tagged knock-in of adhesion molecules or signaling proteins enables localization and interaction studies during leukocyte attachment. Knock-in of risk variants can test whether a specific allele alters endothelial activation or adhesion.
Overexpression
CRISPR-based overexpression or cDNA overexpression of candidate genes in endothelial cells tests sufficiency for leukocyte attachment. Overexpression of adhesion molecules such as VCAM-1 or ICAM-1 would be predicted to increase leukocyte attachment, providing a gain-of-function complement to knockout studies. Overexpression models are also useful for testing whether a gene can drive endothelial activation in the absence of external stimuli.
How EDITGENE Supports leukocyte adhesion to arterial endothelial cell Research
Researchers studying leukocyte adhesion to arterial endothelial cell-related genes often need to determine whether a candidate gene is causally involved in endothelial activation, adhesion molecule expression, or leukocyte attachment. Establishing causality requires controlled genetic perturbation in relevant cell models, coupled with functional adhesion assays. EDITGENE provides the necessary tools to generate and validate such models.
Contact EDITGENE today to design your custom CRISPR model for leukocyte adhesion to arterial endothelial cell research.
Frequently Asked Questions About leukocyte adhesion to arterial endothelial cell
What is GO:0061757?
GO:0061757 is the Gene Ontology term for leukocyte adhesion to arterial endothelial cell, defined as the attachment of a leukocyte to an arterial endothelial cell via adhesion molecules.
What genes are involved in leukocyte adhesion to arterial endothelial cell?
Genes encoding adhesion molecules such as VCAM-1 and ICAM-1, signaling components including p38 MAPK alpha and NF-kappaB, and modulators such as CD40L, Annexin A8, and myeloperoxidase have been implicated.
Why is leukocyte adhesion to arterial endothelium important in atherosclerosis?
Atherosclerosis is an inflammatory disease in which leukocyte recruitment to the arterial wall is a central event, and leukocyte adhesion to arterial endothelium is an early step in this process.
How is leukocyte adhesion to arterial endothelial cells measured experimentally?
It is commonly measured using static or flow-based adhesion assays in which labeled leukocytes are incubated with activated endothelial monolayers and attached cells are quantified.
What signaling pathways regulate leukocyte adhesion to arterial endothelium?
The p38 MAPK alpha and NF-kappaB pathways are central regulators of endothelial activation and adhesion molecule expression, and mitochondrial fission provides an additional modulatory input.
Can CRISPR be used to study GO:0061757?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can be combined with leukocyte adhesion assays to test whether specific genes are required or sufficient for attachment.
What diseases are associated with leukocyte adhesion to arterial endothelial cells?
Atherosclerosis, vascular inflammation, and thoracic aortic aneurysm in Marfan disease have been linked to this process or its upstream regulators.
What is the role of CD40L in leukocyte adhesion to arterial endothelium?
Endothelial CD40L has been identified as a pro-atherogenic adhesion receptor in the inflamed vasculature, contributing to leukocyte engagement.
Does mitochondrial fission affect leukocyte adhesion to arterial endothelium?
Mitochondrial fission has been shown to mediate endothelial inflammation, which supports leukocyte adhesion.
How can I create a knockout cell model for a gene involved in leukocyte adhesion to arterial endothelial cells?
EDITGENE provides CRISPR knockout cell model services that can be combined with adhesion assays to test gene function in endothelial cells.
Conclusion
GO:0061757 leukocyte adhesion to arterial endothelial cell defines a specific, assayable cellular event that is central to inflammatory vascular biology. The process is driven by endothelial activation and adhesion molecule expression, regulated by signaling pathways including p38 MAPK alpha and NF-kappaB, and modulated by factors such as mitochondrial fission and CD40L. Its relevance to atherosclerosis and arterial aneurysm formation makes it a valuable annotation target for cardiovascular research. Researchers can interrogate GO:0061757 using adhesion assays combined with CRISPR-based genetic perturbation. Knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate genes, while library screening and bioinformatics approaches support discovery of novel regulators. These tools make the process accessible for mechanistic and translational studies.
References
- 1. Libby P. 2024. Inflammation and the pathogenesis of atherosclerosis.. Vascul Pharmacol 154:107255 PMID: 38157682
- 2. Kaur K et al.. 2023. Crizanlizumab in sickle cell disease.. Pain Manag PMID: 37850353
- 3. Gutiérrez-Muñoz C et al.. 2025. Annexin A8 deficiency delays atherosclerosis progression.. Clin Transl Med 15(1):e70176 PMID: 39835780
- 4. Menon SN et al.. 2023. Neflamapimod inhibits endothelial cell activation, adhesion molecule expression, leukocyte attachment and vascular inflammation by inhibiting p38 MAPKα and NF-κB signaling.. Biochem Pharmacol 214:115683 PMID: 37429422
- 5. Forrester SJ et al.. 2020. Mitochondrial Fission Mediates Endothelial Inflammation.. Hypertension 76(1):267-276 PMID: 32389075
- 6. Mehrkens D et al.. 2026. Myeloperoxidase aggravates thoracic aortic aneurysm formation in Marfan disease.. Cardiovasc Res 122(2):230-244 PMID: 41403006
- 7. Scherrer P et al.. 2025. Endothelial CD40L serves as a pro-atherogenic adhesion receptor in the inflamed vasculature.. Atherosclerosis 411:120517 PMID: 41314760
- 8. Libby P. 2000. Changing concepts of atherogenesis.. J Intern Med 247(3):349-58 PMID: 10762452
